Meropenem

Meropenem is an ultra-broad spectrum injectable antibiotic used to treat a wide variety of infections, including meningitis and pneumonia. It is a beta-lactam and belongs to the subgroup of carbapenem, similar to imipenem and ertapenem. Meropenem was originally developed by Sumitomo Pharmaceuticals. It is marketed outside Japan by AstraZeneca with the brand names Merrem and Meronem. Other brand names include Zwipen (India, Marketed by Nucleus) Mepem (Taiwan) Meropen (Japan, Korea) and Neopenem (NEOMED India) . It gained FDA approval in July 1996. It penetrates well into many tissues and body fluids including the cerebrospinal fluid, bile, heart valves, lung, and peritoneal fluid.

Properties:

Appearance & Physical State: White or almost white powder Complies

Density: 1.42 g/cm3

Boiling Point: 627.4ºC at 760 mmHg

Flash Point: 333.2ºC

Refractive Index: 1.639

Antibiotics chemical Related Products:

Doripenem Hydrate; Linezolid; Cefoselis Sulfate; Tebipenem; Tebipenem pivoxil; Amphotericin B; Aztreonam; Cefaclor; Tobramycin; Roxithromycin; Enrofloxacin; Nadifloxacin; Gamithromycin; Orbifloxacin; Polymyxin B Sulfate; Kanamycin; Tildipirosin; Ertapenem Sodium; Faropenem sodium; Ceftizoxime

[1]. Slaney, L., et al., In-vitro activity of meropenem against Neisseria gonorrhoeae, Haemophilus influenzae and H. ducreyi from Canada and Kenya. J Antimicrob Chemother, 1989. 24 Suppl A: p. 183-6.

[2]. Yang, Y.J. and D.M. Livermore, Interactions of meropenem with class I chromosomal beta-lactamases. J Antimicrob Chemother, 1989. 24 Suppl A: p. 207-17.

[3]. Makino, J., et al., [Pharmacokinetic study of penetration of meropenem into pleural effusion in patients with pleurisy]. Jpn J Antibiot, 2002. 55(1): p. 77-88.